These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 36737518)

  • 1. Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation.
    Honda A; Tahara N; Tahara A; Bekki M; Maeda-Ogata S; Sugiyama Y; Igata S; Nishino Y; Matsui T; Kurata S; Abe T; Yamagishi SI; Fukumoto Y
    J Nucl Cardiol; 2023 Aug; 30(4):1613-1626. PubMed ID: 36737518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
    Zemmrich C; Lüders S; Gansz A; Sturm CD; Fimmers R; Nadal J; Schmieder RE; Schrader J; Bramlage P
    J Clin Hypertens (Greenwich); 2013 Nov; 15(11):815-9. PubMed ID: 24102831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular Inflammation Evaluated by [18F]-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Is Associated With Endothelial Dysfunction.
    Honda A; Tahara N; Nitta Y; Tahara A; Igata S; Bekki M; Nakamura T; Sugiyama Y; Kaida H; Kurata S; Fujimoto K; Abe T; Enomoto M; Adachi H; Narula J; Yamagishi S; Fukumoto Y
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1980-8. PubMed ID: 27386941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.
    Erdine S
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):31-44. PubMed ID: 22222315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
    Neutel J; Shojaee A; Maa JF
    Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
    Ruilope LM; Schaefer A
    Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study.
    Mourad JJ; Le Jeune S
    Clin Drug Investig; 2009; 29(6):419-25. PubMed ID: 19432501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
    Redon J; Pichler G;
    J Hypertens; 2016 Feb; 34(2):359-67. PubMed ID: 26867060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
    Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.
    Miyashita Y; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohira M; Oyama T; Shirai K
    J Atheroscler Thromb; 2009 Oct; 16(5):621-6. PubMed ID: 19907103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension.
    Higashi Y; Oshima T; Sasaki S; Nakano Y; Kambe M; Matsuura H; Kajiyama G
    Hypertension; 1998 Jul; 32(1):16-24. PubMed ID: 9674632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase.
    Takiguchi S; Ayaori M; Uto-Kondo H; Iizuka M; Sasaki M; Komatsu T; Takase B; Adachi T; Ohsuzu F; Ikewaki K
    Hypertens Res; 2011 Jun; 34(6):686-92. PubMed ID: 21307868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olmesartan/amlodipine: a review of its use in the management of hypertension.
    Kreutz R
    Vasc Health Risk Manag; 2011; 7():183-92. PubMed ID: 21490944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on Blood Pressure Variability in Black African Patients: Secondary Analyses of the CREOLE Trial.
    Ojji DB; Cornelius V; Partington G; Francis V; Pandie S; Smythe W; Hickman N; Barasa F; Damasceno A; Dzudie A; Jones E; Ingabire PM; Mondo C; Ogah O; Ogola E; Sani MU; Shedul GL; Shedul G; Rayner B; Sliwa K; Poulter N;
    Hypertension; 2022 Nov; 79(11):2593-2600. PubMed ID: 36052684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
    Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
    Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients.
    Derosa G; Cicero AF; Carbone A; Querci F; Fogari E; D'Angelo A; Maffioli P
    Inflammation; 2014 Feb; 37(1):154-62. PubMed ID: 24018781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.